This site is intended for US healthcare
professionals only.
VERONA PATHWAY PLUSTM:

Working to clear the pathway
to treatment

Verona Pathway Plus is a patient support program that is available to you and your patients during treatment. It provides tools, resources, education, and assistance to help navigate access and affordability for patients who have been prescribed Ohtuvayre.

Since prescriptions are filled only through our network of Specialty Pharmacies (SPs), Verona Pathway Plus coordinates with the right SP to provide convenient delivery directly to your patients.

Verona Pathway Plus logo

Call:
833-372-8492

Back to top
Enroll Your Patient
Financial Coverage
Dedicated Support Team
Back to top

Prescribing through Verona Pathway Plus is easy

Receive coverage and access support for Ohtuvayre through Verona Pathway Plus and direct delivery of prescriptions to your patients through our exclusive Durable Medical Equipment (DME) Accredited Specialty Pharmacy (SP) Network.

Step 1

Complete the Prescription and Patient Consent Form
  • The Prescription Form includes the Ohtuvayre and DME prescriptions
  • Ensure your patient completes the Patient Consent Form during the office visit to expedite Verona Pathway Plus enrollment for additional support

Step 2

Submit via Fax

Fax the Ohtuvayre Prescription Form and the Patient Consent Form to
833-392-8999.

Verona Pathway Plus Offers Support Throughout Treatment

Coverage and Affordability

Support and Education

Prescription Fulfillment

Financial Assistance

Copay Program

Eligible commercially insured patients may pay as little as $0 per month for Ohtuvayre.*

Ohtuvayre Bridge Program

Verona Pathway Plus may be able to help with starting treatment if there is a coverage delay with your patient’s insurance. You must check the Bridge Program Prescription on the Patient Enrollment Form for your patient to be considered for the Bridge Program.

Patient Assistance Program

For patients who do not have insurance, are underinsured, or are in a situation where Ohtuvayre is not covered by their insurance plan, Verona Pathway Plus can provide financial assistance options, such as the Patient Assistance Program.

  • Verona Pathway Plus can check to see if your patient qualifies, based on the program’s eligibility criteria.

*Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

Our Dedicated Team is Available to You and Your Patients

Care Coordinators

Verona Pathway Plus Care Coordinators will support your office by providing access and product information to help patients throughout treatment. This includes:

  • Benefits investigations (BIs)
  • Medication and nebulizer access
  • Providing eligible patients with financial assistance options
  • Coordinating with the appropriate specialty pharmacy (SP) in our Durable Medical Equipment (DME)-accredited SP network to deliver Ohtuvayre directly to your patients.
  • Offering support and education throughout Ohtuvayre treatment

Field Reimbursement Managers (FRMs)

FRMs will provide your office staff with access and reimbursement education and support resources to help your patients navigate coverage from payers. This includes:

  • Education on how to prescribe Ohtuvayre through Verona Pathway Plus
  • Insurance coverage education and support
  • Information to help resolve access issues, including prior authorizations (PAs) and appeals processes

Prescriptions are filled only through our exclusive DME-accredited SP Network. They will work with your office and patients in order to:

  • Assist with the PA process
  • Answer questions, offer treatment support, and provide education about Ohtuvayre
  • Ship Ohtuvayre and necessary supplies directly to your patients
  • Provide refill management by text and Online Portal

If your practice needs to contact a Care Coordinator, please call us Monday through Friday, between 8:00 AM and 8:00 PM ET.

A Care Coordinator can also connect you to a pharmacist.

Call: 833-372-8492

Learn more about Ohtuvayre

Warnings and Precautions:

Acute Episodes of Bronchospasm Ohtuvayre should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled, short-acting bronchodilator.

Paradoxical Bronchospasm As with other inhaled medicines, Ohtuvayre may produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with Ohtuvayre, it should be treated immediately with an inhaled, short-acting bronchodilator. Ohtuvayre should be discontinued immediately and alternative therapy should be instituted.

Psychiatric Events Including Suicidality Before initiating treatment with Ohtuvayre, healthcare providers should carefully weigh the risk and benefits of treatment with Ohtuvayre in patients with a history of depression and/or suicidal thoughts or behavior. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts, or other mood changes, and if such changes occur to contact their healthcare provider. Healthcare providers should carefully evaluate the risks and benefits of continuing treatment with Ohtuvayre if such events occur.

Treatment with Ohtuvayre is associated with an increase in psychiatric adverse reactions. Psychiatric events including suicide-related adverse reactions were reported in clinical studies in patients who received Ohtuvayre (1 suicide attempt and 1 suicide). Additionally, the most commonly reported psychiatric adverse reactions in the pooled 24-week safety population were insomnia (6 patients [0.6%] Ohtuvayre 3 mg; 2 patients [0.3%] placebo), and anxiety (2 patients [0.2%] Ohtuvayre 3 mg; 1 patient [0.2%] placebo). Depression-related reactions including depression, major depression, and adjustment disorder with depressed mood occurred in 4 patients [0.4%] receiving Ohtuvayre and no patients receiving placebo.

Adverse Reactions: The most common adverse reactions ≥1% in Ohtuvayre and greater than placebo in the pooled population were back pain 1.8%, hypertension 1.7%, urinary tract infection 1.3%, and diarrhea 1.0%.

These are not all of the possible risks associated with Ohtuvayre. Please see Full Prescribing Information for Ohtuvayre.

To report suspected adverse reactions, contact Verona Pharma, Inc. at
1-888-672-0371 or FDA at
1-800-FDA-1088 or
www.fda.gov/medwatch.